Ionis Pharmaceuticals Inc (IONS)

Trade IONS now with
3/28/2022 7:34:53 AM Biogen : Phase 1 Study Of BIIB078 On Amyotrophic Lateral Sclerosis Did Not Meet Any Secondary Efficacy Endpoints
2/24/2022 7:22:51 AM Ionis Q4 EPS $1.41 Vs. Loss/shr $2.54 Prior Year
1/31/2022 7:08:17 AM Pfizer, Ionis Announce Discontinuation Of Vupanorsen Clinical Program For CV Risk Reduction And Hypertriglyceridemia
1/24/2022 7:13:01 AM Ionis Pharma Announces Eplontersen Receives Orphan Drug Designation From FDA
1/18/2022 12:50:55 AM Ionis' Partner Roche To Evaluate Tominersen For Huntington's Disease In New Phase 2 Trial
1/4/2022 7:35:28 AM Biogen Exercises Option To Obtain From Ionis A Worldwide License To Develop BIIB115/ION306
12/29/2021 2:02:05 AM AstraZeneca Closes Global Commercialisation Agreement With Ionis Pharma For Eplontersen
12/7/2021 2:03:35 AM AstraZeneca And Ionis Sign Deal To Develop Eplontersen
11/24/2021 6:34:00 AM Ionis Says Pfizer Reports Topline Results From Phase 2b Study Of Vupanorsen On Non-HDL-C
11/3/2021 7:23:58 AM Ionis Q3 Net Loss $82 Mln Vs. Net Loss $37 Mln Last Year
8/2/2021 9:31:32 AM Lp HORIZON Achieves 50% Enrollment In Trial To Assess Efficacy Of Pelacarsen In Reducing Recurrent Cardiovascular Events